我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
31
19 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
18
58.1%
已完成
5
16.1%
尚未招募
1
3.2%
招募中
终止
2
6.5%
暂无批准数据
- Opthea's sozinibercept (OPT-302) demonstrates potential to enhance visual outcomes in wet age-related macular degeneration patients without competing with standard anti-VEGF-A therapies. - The company's crucial COAST and ShORe trials are advancing on schedule, with results anticipated in early and mid-2025, leading to potential regulatory filing in Q1 2026. - Leading analysts, including Leerink Partners' Marc Goodman, maintain bullish outlook on Opthea's stock, highlighting the drug's commercial promise in addressing unmet needs in ophthalmology.
